{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Sustained complete response (sCR)"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Complete response (CR)"},{"measurements":[{"groupId":"OG000","value":"16"}],"title":"Very good partial response (VGPR)"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Partial response (PR)"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Minimal response (MR)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Best responses to E-RVD was assessed using International Myeloma Working Group (IMWG) response criteria: Partial Response (PR) defined as 50% reduction of serum M-protein and reduction in 24h urinary M-protein by ≥90% or to \\<200mg/24h; Very Good Partial Response (VGPR) defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \\<100mg/24h; Complete Response (CR) defined as negative immunofixation on serum and urine and, disappearance of any soft tissue plasmacytomas and, \\<5% plasma cells in BM; Stringent Complete Response (sCR) defined as normal FLC ratio and absence of clonal cells in BM by immunohistochemistry or 2-4 color flow cytometry.","groups":[{"description":"Participants will receive therapy with the combination of lenalidomide, bortezomib, and dexamethasone and elotuzumab (E-RVD). Induction cycles (1 to 8) are 21-day cycles.\n\n* Elotuzumab will be administered by intravenous (IV) infusion\n* Bortezomib as a subcutaneous injection\n* Lenalidomide single daily oral dose\n* Dexamethasone as oral tablets and IV infusion\n* Stem cell mobilization will be performed for all subjects at the end of Cycle 4.\n\nSubjects may elect to stop E-RVD at the end of Cycle 4 and proceed to autologous SCT. Subjects who do not proceed to SCT may receive 8 cycles of induction therapy.\n\nThe maintenance schedule (28 days) will start after 8 cycles of induction regimen for subjects not proceeding with SCT, or after recovery from SCT for subjects proceeding with it.\n\nMaintenance therapy with E-RVD will be administered to all patients, with the specific maintenance regimen determined by risk category.","id":"OG000","title":"All Patients Treated With E-RVD (40 Patients)."}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Best responses to E-RVD in the safety population, defined as participants with Multiple Myeloma who received one or more dose of elotuzumab. Out of the 40 participants included in the safety population, one participant did not receive or more dose of elotuzumab, and was not included in the best response analysis population.","reportingStatus":"POSTED","timeFrame":"Participants were followed up to 273.6 weeks.","title":"Best Responses to E-RVD.","type":"SECONDARY","unitOfMeasure":"Participants"}